In Vivo detection of human TRPV6-rich tumors with anti-cancer peptides derived from soricidin

Download
  1. (PDF, 1 MB)
  2. Get@NRC: In Vivo detection of human TRPV6-rich tumors with anti-cancer peptides derived from soricidin (Opens in a new window)
DOIResolve DOI: http://doi.org/10.1371/journal.pone.0058866
AuthorSearch for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for:
TypeArticle
Journal titlePLoS ONE
ISSN1932-6203
Volume8
Issue3
Article numbere58866
AbstractSoricidin is a 54-amino acid peptide found in the paralytic venom of the northern short-tailed shrew (Blarina brevicauda) and has been found to inhibit the transient receptor potential of vallinoid type 6 (TRPV6) calcium channels. We report that two shorter peptides, SOR-C13 and SOR-C27, derived from the C-terminus of soricidin, are high-affinity antagonists of human TRPV6 channels that are up-regulated in a number of cancers. Herein, we report molecular imaging methods that demonstrate the in vivo diagnostic potential of SOR-C13 and SOR-C27 to target tumor sites in mice bearing ovarian or prostate tumors. Our results suggest that these novel peptides may provide an avenue to deliver diagnostic and therapeutic reagents directly to TRPV6-rich tumors and, as such, have potential applications for a range of carcinomas including ovarian, breast, thyroid, prostate and colon, as well as certain leukemia's and lymphomas.
Publication date
PublisherPLOS
LanguageEnglish
AffiliationMedical Devices; Aquatic and Crop Resource Development; Human Health Therapeutics; National Research Council Canada
Peer reviewedYes
NRC numberNRC-HHT-53263
NPARC number21269759
Export citationExport as RIS
Report a correctionReport a correction
Record identifier45f91680-00ea-4763-8ce9-6880089e2685
Record created2013-12-13
Record modified2016-05-09
Bookmark and share
  • Share this page with Facebook (Opens in a new window)
  • Share this page with Twitter (Opens in a new window)
  • Share this page with Google+ (Opens in a new window)
  • Share this page with Delicious (Opens in a new window)